(Total Views: 413)
Posted On: 10/27/2021 10:37:04 AM
Post# of 587
United Health Products Provides Regulatory Update
PRESS RELEASE OCT 27, 2021 09:07 EDT
HENDERSON, Nev., October 27, 2021 (Newswire.com) - United Health Products, Inc. (OTCPK: UEEC), (UHP) today confirmed it has submitted its response to the Food & Drug Administration's (FDA) most recent questions and comments on the company's Pre-market Approval (PMA) application. At this time there are no outstanding FDA information requests to UHP, however, the FDA reserves the rights under its review process to request additional information at any time.
As previously disclosed, UHP's PMA application is currently in Substantive Review by the FDA. Receipt of a PMA is a condition to the company's ability to market is HemoStyp products for human surgical procedures. There can be no assurance that a PMA will be granted by the FDA.
Investor relations:
Philippe Niemetz
PRESS RELEASE OCT 27, 2021 09:07 EDT
HENDERSON, Nev., October 27, 2021 (Newswire.com) - United Health Products, Inc. (OTCPK: UEEC), (UHP) today confirmed it has submitted its response to the Food & Drug Administration's (FDA) most recent questions and comments on the company's Pre-market Approval (PMA) application. At this time there are no outstanding FDA information requests to UHP, however, the FDA reserves the rights under its review process to request additional information at any time.
As previously disclosed, UHP's PMA application is currently in Substantive Review by the FDA. Receipt of a PMA is a condition to the company's ability to market is HemoStyp products for human surgical procedures. There can be no assurance that a PMA will be granted by the FDA.
Investor relations:
Philippe Niemetz
(0)
(0)
